Cannara Biotech

Cannara Biotech Financial Leverage

The Financial Leverage (Equity Multiplier) of Cannara Biotech (LOVE.V) as of Nov 16, 2026 is 1.65. In the previous year, Financial Leverage (Equity Multiplier) was 1.76 — a change of -6.21% (lower).

Financial Leverage

1.65

YoY

-6.21%

Last updated:

Financial Leverage (Equity Multiplier) of Cannara Biotech is 2025 1.65 . Financial Leverage (Equity Multiplier) of Cannara Biotech was 2024 1.76 . It decreases by -6.21% lower compared to the previous year.

The Cannara Biotech Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.96 CAD
Jan 1, 2019
1.44 CAD
Jan 1, 2020
1.43 CAD
Jan 1, 2021
1.44 CAD
Jan 1, 2022
1.88 CAD
Jan 1, 2023
1.77 CAD
Jan 1, 2024
1.76 CAD
Jan 1, 2025
1.65 CAD
The Cannara Biotech Financial Leverage history
YEARFinancial LeverageYoY
1.65-6.21%
1.76-0.88%
1.77-5.72%
1.88+31.15%
1.44+0.39%
1.43-0.99%
1.44-26.24%
1.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cannara Biotech Stock analysis

What does Cannara Biotech do? Cannara Biotech, Inc. generates revenue through its Cannabis operations segment, which includes the cultivation, processing, and sale of dried cannabis and cannabis derivatives for the Canadian market. The company's brand portfolio features Tribal, Nugz, and Orchid CBD, with Orchid CBD specifically targeting the wellness market as a premium CBD-dominant product. The Real estate operations segment involves the management of Farnham and Valleyfield properties, contributing to the company's overall revenue streams. The firm's two mega facilities in Quebec, spanning over 1,650,000 square feet, enable annualized cultivation output of 100,000 kilograms, supporting both product lines and real estate activities. The primary buyers for Cannara's cannabis products are Canadian consumers and businesses within the regulated cannabis market. Tribal and Nugz are positioned as premium cannabis brands, while Orchid CBD serves the wellness segment with its CBD-dominant offerings. Real estate operations focus on leasing and managing the Farnham and Valleyfield buildings, which are part of the company's owned properties. The company's subsidiary structure, including Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc.), supports both operational segments without external partnerships or third-party dependencies. Cannara Biotech's revenue model combines direct sales of cannabis products under its brand portfolio with property management income from its real estate holdings. The company's two facilities in Quebec provide the scale necessary for both cultivation and real estate operations, with the Cannabis operations segment driving most of the product-related sales. The Real estate operations segment complements this by generating steady income from the Farnham and Valleyfield properties, which are integral to the company's asset base. Cannara Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cannara Biotech stock

Financial Leverage (Equity Multiplier) of Cannara Biotech is 1.65 in 2025.

Financial Leverage (Equity Multiplier) of Cannara Biotech changed from 1.76 to 1.65, representing a -6.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Cannara Biotech since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Cannara Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cannara Biotech

All Key Metrics — Cannara Biotech